Welcome to our dedicated page for Ascendis Pharma SEC filings (Ticker: ASND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ascendis Pharma A/S (ASND) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. Ascendis files annual reports on Form 20-F and furnishes interim updates on Form 6-K, which include clinical, regulatory, financial, and corporate information related to its TransCon-based therapies.
In these filings, investors can review details on Ascendis’ pharmaceutical preparation manufacturing activities, including revenue from commercial products such as YORVIPATH (TransCon PTH) for adults with hypoparathyroidism and SKYTROFA (TransCon hGH) for growth hormone deficiency. Unaudited condensed consolidated interim financial statements, management’s discussion and analysis, and segment information by geography (North America, Europe, and rest of world) are typically included in quarterly 6-K submissions.
Filings also describe the status of key pipeline programs like TransCon CNP for children with achondroplasia, combination therapy with TransCon CNP and TransCon hGH in the COACH trial, and TransCon IL-2 β/γ in oncology, along with updates on regulatory reviews by the U.S. Food and Drug Administration and the European Medicines Agency. Additional 6-Ks may cover warrant grants, share capital changes, and the operation of equity compensation plans and share repurchase programs.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy 20-F and 6-K filings, helping users quickly understand revenue drivers, operating results, and key clinical or regulatory events. Real-time updates from EDGAR ensure that new Ascendis filings, including financial statements and other material disclosures, are available promptly, while structured access makes it easier to locate specific reports relevant to ASND analysis.
Ascendis Pharma A/S is redeeming all $575.0 million of its 2.25% Convertible Senior Notes due 2028 on May 6, 2026. Noteholders will receive cash equal to 100% of principal plus accrued interest, or can choose to convert into ordinary shares before the redemption.
As of April 21, 2026, each $1,000 principal amount is redeemable for about $1,002.19, or convertible into 6.0118 shares, implying a conversion price of roughly $166.34 per share. During a special make-whole period, the conversion rate temporarily increases to 6.3232 shares, lowering the effective conversion price to about $158.15 per share and potentially increasing dilution.
Ascendis Pharma A/S filed a report to correct the identification code for its ordinary shares following their direct listing on The Nasdaq Global Select Market. The company clarifies that the applicable International Securities Identification Number is now DK0060615755, replacing the previously disclosed DK0060606333.
The report is also incorporated by reference into multiple existing registration statements on Form S-8 and Form F-3. The company confirms that the CUSIP number K08588103 and the Nasdaq ticker symbol ASND for its ordinary shares remain the same.
Ascendis Pharma A/S has shifted its Nasdaq presence from American Depositary Shares to directly listed ordinary shares. The ordinary shares began trading on the Nasdaq Global Select Market under the ticker ASND on April 20, 2026.
The company implemented a mandatory exchange in which each outstanding ADS was converted into one ordinary share listed on Nasdaq. The last trading day for ADSs was April 17, 2026, and by April 20, 2026 all ADSs had been exchanged for ordinary shares.
Ascendis Pharma A/S reported that its board granted an aggregate of 32,310 warrants to certain employees under Appendix 1a to its Articles of Association. Each warrant gives the right to subscribe for one ordinary share at an exercise price of US $249.84 per share, matching the closing price of the company’s American Depositary Shares on the grant date.
Subject to earlier vesting upon certain exit events and continued service, 25% of the warrants will vest one year after the grant date, while the remaining 75% will vest in equal monthly installments over the following 36 months. After this grant, warrants to subscribe for an additional 1,611,843 shares remain available for future grants under the Articles of Association.
Ascendis Pharma A/S is transitioning from ADSs to a direct listing of its ordinary shares on Nasdaq. The company plans to list its ordinary shares on The Nasdaq Global Select Market, with trading expected to begin on April 20, 2026 under the existing ticker “ASND.”
All outstanding American Depositary Shares will be mandatorily exchanged for ordinary shares on a one-for-one basis. The last trading day for ADSs on Nasdaq is expected to be April 17, 2026, after which holders will automatically receive ordinary shares through their brokers’ DTC accounts.
Ascendis Pharma A/S is transitioning from ADSs to a direct listing of its ordinary shares on Nasdaq. The company plans to list its ordinary shares on The Nasdaq Global Select Market, with trading expected to begin on April 20, 2026 under the existing ticker “ASND.”
All outstanding American Depositary Shares will be mandatorily exchanged for ordinary shares on a one-for-one basis. The last trading day for ADSs on Nasdaq is expected to be April 17, 2026, after which holders will automatically receive ordinary shares through their brokers’ DTC accounts.
Ascendis Pharma A/S reports new Week 52 data from its Phase 2 COACH Trial, studying combination therapy with once-weekly TransCon CNP and once-weekly TransCon hGH in children with achondroplasia. The company states that TransCon hGH accelerated TransCon CNP’s benefits beyond linear growth, with substantial improvements in arm span, spinal canal dimensions, and lower limb alignment.
Ascendis notes previously reported Week 52 results from the same trial showing mean annualized growth velocity above the 97th percentile of average-stature children, with maintained safety and tolerability and no acceleration of bone age. The report is incorporated by reference into existing Form S-8 and Form F-3 registration statements and includes extensive forward-looking statement language outlining clinical, regulatory, manufacturing, commercial, and financial risks referenced to Ascendis’ Form 20-F and future SEC reports.
Ascendis Pharma A/S reports new Week 52 data from its Phase 2 COACH Trial, studying combination therapy with once-weekly TransCon CNP and once-weekly TransCon hGH in children with achondroplasia. The company states that TransCon hGH accelerated TransCon CNP’s benefits beyond linear growth, with substantial improvements in arm span, spinal canal dimensions, and lower limb alignment.
Ascendis notes previously reported Week 52 results from the same trial showing mean annualized growth velocity above the 97th percentile of average-stature children, with maintained safety and tolerability and no acceleration of bone age. The report is incorporated by reference into existing Form S-8 and Form F-3 registration statements and includes extensive forward-looking statement language outlining clinical, regulatory, manufacturing, commercial, and financial risks referenced to Ascendis’ Form 20-F and future SEC reports.
Ascendis Pharma A/S reports that the U.S. FDA has granted orphan drug exclusivity to YUVIWEL (navepegritide; developed as TransCon® CNP), and that YUVIWEL is now commercially available in the United States. YUVIWEL is the first and only once-weekly treatment approved to increase linear growth in children 2 years and older with achondroplasia and open epiphyses, providing continuous systemic exposure to CNP over the weekly dosing interval. The orphan drug exclusivity for YUVIWEL runs through February 27, 2033.
Ascendis Pharma A/S director Jean Jacques Bienaimé filed an initial ownership report showing a warrant position rather than common shares. He directly holds warrants exercisable for 9,160 Ordinary Shares, with an exercise price of $172.35 per share and expiration on June 10, 2035. The warrants vest 25% on June 10, 2026 and then in 36 equal monthly installments. The filing also indicates he holds no Ordinary Shares directly as of the reporting date, and notes that the position includes American Depositary Shares, with each ADS representing one Ordinary Share.
Ascendis Pharma A/S reports the closing of an exercise window for its outstanding warrants linked to ordinary shares. During this period, warrant holders exercised rights resulting in registered share capital increases of nominal DKK 399,438, bringing total share capital to nominal DKK 62,376,846.
The company issued 399,438 new ordinary shares against average cash consideration of approximately USD $92.10 per share, based on the DKK-USD exchange rate on March 30, 2026. Ascendis amended its articles of association to reflect the higher share capital, and the updated articles are attached as an exhibit.
Ascendis Pharma A/S reported the results of its Annual General Meeting, where shareholders representing 56,234,042 ordinary shares, or 90.16% of shares outstanding, were present or represented. All agenda items were approved with strong support across the ballot.
Shareholders adopted the audited annual report for the year ended December 31, 2025 and discharged the Board of Directors and management from liability. They also approved carrying forward the consolidated loss of EUR 228 million for 2025 into 2026 via accumulated deficit.
All incumbent Board members were re-elected and Jean-Jacques Bienaimé joined as a new non-executive director, with terms running until the 2027 annual meeting. Shareholders also renewed authority allowing the Board, until March 22, 2031, to repurchase up to nominal DKK 1,000,000 of shares or equivalent American Depositary Shares as treasury shares.